Advertisement

Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone

Laurel E. WilliamsDepartment of Small Animal Clinical Sciences, University of Minnesota, St. Paul, MN 55108.
Present address is Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Laurel E. Williams in
Current site
Google Scholar
PubMed
Close
 DVM
,
Nilanjana BanerjiDepartment of Veterinary Pathobiology College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108.

Search for other papers by Nilanjana Banerji in
Current site
Google Scholar
PubMed
Close
 MSc
,
Jeffrey S. KlausnerDepartment of Small Animal Clinical Sciences, University of Minnesota, St. Paul, MN 55108.

Search for other papers by Jeffrey S. Klausner in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Vivek KapurDepartment of Veterinary Pathobiology, University of Minnesota, St. Paul, MN 55108.

Search for other papers by Vivek Kapur in
Current site
Google Scholar
PubMed
Close
 BVSc, PhD
, and
Sagarika KanjilalDepartment of Veterinary Pathobiology, College of Veterinary Medicine, and the Department of Dermatology, College of Medicine, University of Minnesota, St. Paul, MN 55108.

Search for other papers by Sagarika Kanjilal in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To establish 2 vaccine-associated feline sarcoma (VAFS) cell lines and to determine their in vitro sensitivity to the chemotherapeutic agents doxorubicin and mitoxantrone.

Sample Population—Tumor specimens collected from 2 cats undergoing surgery for removal of vaccine- associated sarcomas.

Procedures—Tumor specimens were minced and treated with trypsin under aseptic conditions to obtain single-cell suspensions, which were then cultured in vitro in medium supplemented with 5% heat-inactivated fetal bovine serum. Growth rates and sensitivity after 24 hours of exposure to various concentrations (0.1 to 100 μg/ml) of doxorubicin and mitoxantrone were assessed for each cell line. Survival of cells was estimated 3 days after exposure to the 2 agents, and the concentration of each drug that resulted in a 50% reduction in the number of viable cells (IC50) was calculated.

Results—Two tumor-derived cell lines (FSA and FSB) were successfully established and determined to be sensitive to doxorubicin and mitoxantrone. Under the conditions tested, the IC50 of doxorubicin were 0.6 and 1.5 μg/ml for cell lines FSB and FSA, respectively. The IC50 of mitoxantrone was 0.4 μg/ml for both cell lines.

Conclusions and Clinical Relevance—The establishment of VAFS cell lines provides a tool for the in vitro screening of antitumor drugs. Doxorubicin and mitoxantrone were effective in decreasing the number of viable cells in the 2 cell lines tested. Both of these anthracycline antibiotics have been used to treat various neoplasias in cats, and their efficacy for adjuvant treatment of vaccine-associated sarcomas should be further evaluated. (Am J Vet Res 2001;62:1354–1357).

Abstract

Objective—To establish 2 vaccine-associated feline sarcoma (VAFS) cell lines and to determine their in vitro sensitivity to the chemotherapeutic agents doxorubicin and mitoxantrone.

Sample Population—Tumor specimens collected from 2 cats undergoing surgery for removal of vaccine- associated sarcomas.

Procedures—Tumor specimens were minced and treated with trypsin under aseptic conditions to obtain single-cell suspensions, which were then cultured in vitro in medium supplemented with 5% heat-inactivated fetal bovine serum. Growth rates and sensitivity after 24 hours of exposure to various concentrations (0.1 to 100 μg/ml) of doxorubicin and mitoxantrone were assessed for each cell line. Survival of cells was estimated 3 days after exposure to the 2 agents, and the concentration of each drug that resulted in a 50% reduction in the number of viable cells (IC50) was calculated.

Results—Two tumor-derived cell lines (FSA and FSB) were successfully established and determined to be sensitive to doxorubicin and mitoxantrone. Under the conditions tested, the IC50 of doxorubicin were 0.6 and 1.5 μg/ml for cell lines FSB and FSA, respectively. The IC50 of mitoxantrone was 0.4 μg/ml for both cell lines.

Conclusions and Clinical Relevance—The establishment of VAFS cell lines provides a tool for the in vitro screening of antitumor drugs. Doxorubicin and mitoxantrone were effective in decreasing the number of viable cells in the 2 cell lines tested. Both of these anthracycline antibiotics have been used to treat various neoplasias in cats, and their efficacy for adjuvant treatment of vaccine-associated sarcomas should be further evaluated. (Am J Vet Res 2001;62:1354–1357).